Article

Glaucoma 360 panelist shares industry update on new drugs, drops

Ellie Chabi, MD, Therapeutic Area Head for Glaucoma & Neuroprotection and Lead for Artificial Intelligence Programs within Global Biomedical Science for Santen, provides an update on its glaucoma pipeline.

Ellie Chabi, MD, is Therapeutic Area Head for Glaucoma & Neuroprotection, Lead for Artificial Intelligence Programs within Global Biomedical Science for Santen, shares insights from the industry panel discussion, "Drugs and Drops" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.